Bioinspired chemical probe approach targeting telomerase reverse transcriptase
针对端粒酶逆转录酶的仿生化学探针方法
基本信息
- 批准号:10627813
- 负责人:
- 金额:$ 37.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-01 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
PROJECT SUMMARY
Telomerase has attracted significant attention as a potential target for understanding the aging process and for
the treatment of cancer, since telomeres and telomerase have important roles in the transformation and
survival of cancer cells. Previous prevailing strategies for targeting telomerase were based on the assumption
that in cancer cells, telomere-length maintenance was the sole pro-survival function of this assembly. However,
increasingly evidence strongly indicates that a) inhibition of the telomere-lengthening activity of telomerase is
not a magic bullet treatment for cancer, and b) there is a much larger role for telomerase in key cellular
pathways and these functions are not well understood. Although there have been promising clinical candidates
among telomerase inhibitors, the translation of telomerase-targeted therapies to the clinic remains elusive and
frustratingly slow. This lack of progress is due in part to the growing list of unanswered questions surrounding
telomerase and its role in cancer biology; notably, that hTERT has non-canonical functions separate from
its telomere-lengthening activity that are linked to cancer cell survival. This proposal builds on the
collaboration between the Scheidt and Kron research groups to bring our expertise in chemical synthesis and
cancer biology to bear on key gaps in the knowledge surrounding hTERT, its non-canonical functions, and its
involvement in cancer cell survival. We have discovered that small molecules based on the natural product
chrolactomycin inhibit telomerase and provide a unique platform for probe development. Based on robust
chemical and biological results, we propose to first develop enhanced small molecule probes with improved
efficacy. These compounds will enable precise covalent modification of hTERT catalytic function without
perturbing the overall complex assembly. The following Aims will focus on exploring the use of these new tools
to explore the role(s) of telomerase in DNA damage repair and cell senescence through in-depth analysis of
multiple functions of telomerase as a buffer of cell stress and determinant of cell immortality. The long-term
goal of this project is to understand and leverage the molecular basis for how these natural product-based
molecular tools impact the telomere lengthening and most importantly, non-canonical functions of hTERT.
Ultimately, this new knowledge will drive the development of new understanding of telomerase and its
biological roles.
项目摘要
端粒酶已引起了重大关注,作为理解衰老过程和对的潜在目标
癌症的治疗,因为端粒和端粒酶在转化和
癌细胞的存活。以前的靶向端粒酶的盛行策略是基于假设
在癌细胞中,端粒长度的维持是该组装的唯一促生物性功能。然而,
越来越多的证据表明a)抑制端粒酶端粒延长活性为
不是对癌症的魔术子弹治疗,b)端粒酶在钥匙细胞中的作用要大得多
途径和这些功能尚未很好地理解。尽管有希望的临床候选人
在端粒酶抑制剂中,将端粒酶靶向疗法的翻译为诊所仍然难以捉摸,并且
令人沮丧的缓慢。缺乏进步的部分原因是围绕未解决的问题的列表越来越多
端粒酶及其在癌症生物学中的作用;值得注意的是,HTERT的非规范功能与
与癌细胞存活有关的端粒延长活性。该建议建立在
Scheidt和KRON研究小组之间的合作,以实现我们在化学合成方面的专业知识和
癌症生物学在围绕HTERT的知识,其非典型功能及其的知识中占有关键差距
参与癌细胞存活。我们已经发现基于天然产品的小分子
Chrolactomycin抑制端粒酶,并为探针开发提供独特的平台。基于强大的
化学和生物学效果,我们建议先开发增强的小分子探针,并有所改善
功效。这些化合物将实现HTERT催化功能的精确共价修改
扰动整体复合体组件。以下目标将重点探索这些新工具的使用
通过深入分析,探索端粒酶在DNA损伤修复和细胞衰老中的作用
端粒酶作为细胞应激的缓冲和细胞永生的决定因素的多个功能。长期
该项目的目标是了解和利用这些基于天然产品的分子基础
分子工具会影响端粒延长,最重要的是HTERT的非规范功能。
最终,这一新知识将推动对端粒酶及其其的新理解的发展
生物学作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
Stephen J. Kron其他文献
Procede et appareil de realisation de l'amplification de l'acide nucleique sur un support
在支持下实现酸核放大的过程和装置
- DOI:10.1016/b978-044453125-4.50004-810.1016/b978-044453125-4.50004-8
- 发表时间:19981998
- 期刊:
- 影响因子:1.7
- 作者:C. Adams;T. C. Boles;A. Muir;Stephen J. KronC. Adams;T. C. Boles;A. Muir;Stephen J. Kron
- 通讯作者:Stephen J. KronStephen J. Kron
Yeast actin filaments display ATP-dependent sliding movement over surfaces coated with rabbit muscle myosin.
酵母肌动蛋白丝在涂有兔肌肉肌球蛋白的表面上表现出 ATP 依赖性滑动。
- DOI:
- 发表时间:19921992
- 期刊:
- 影响因子:11.1
- 作者:Stephen J. Kron;D. Drubin;David Botstein;James A. SpudichStephen J. Kron;D. Drubin;David Botstein;James A. Spudich
- 通讯作者:James A. SpudichJames A. Spudich
共 2 条
- 1
Stephen J. Kron的其他基金
PAIRS: Validating telomerase reverse transcriptase (TERT) as an intrinsic vulnerability toward sensitizing cancer to radiation
配对:验证端粒酶逆转录酶 (TERT) 作为癌症对辐射敏感的内在脆弱性
- 批准号:1071839010718390
- 财政年份:2023
- 资助金额:$ 37.83万$ 37.83万
- 项目类别:
Systemic delivery of siRNA by Nanosac for checkpoint blockade immunotherapy of head and neck squamous cell cancer
Nanosac 系统性递送 siRNA 用于头颈鳞状细胞癌的检查点阻断免疫治疗
- 批准号:1033048310330483
- 财政年份:2021
- 资助金额:$ 37.83万$ 37.83万
- 项目类别:
Systemic delivery of siRNA by Nanosac for checkpoint blockade immunotherapy of head and neck squamous cell cancer
Nanosac 系统性递送 siRNA 用于头颈鳞状细胞癌的检查点阻断免疫治疗
- 批准号:1018263010182630
- 财政年份:2021
- 资助金额:$ 37.83万$ 37.83万
- 项目类别:
Systemic delivery of siRNA by Nanosac for checkpoint blockade immunotherapy of head and neck squamous cell cancer
Nanosac 系统性递送 siRNA 用于头颈鳞状细胞癌的检查点阻断免疫治疗
- 批准号:1054782010547820
- 财政年份:2021
- 资助金额:$ 37.83万$ 37.83万
- 项目类别:
Bioinspired chemical probe approach targeting telomerase reverse transcriptase
针对端粒酶逆转录酶的仿生化学探针方法
- 批准号:1021921110219211
- 财政年份:2020
- 资助金额:$ 37.83万$ 37.83万
- 项目类别:
Lipid signaling in cellular senescence and tissue aging
细胞衰老和组织老化中的脂质信号传导
- 批准号:1047454110474541
- 财政年份:2020
- 资助金额:$ 37.83万$ 37.83万
- 项目类别:
Lipid signaling in cellular senescence and tissue aging
细胞衰老和组织老化中的脂质信号传导
- 批准号:1026336610263366
- 财政年份:2020
- 资助金额:$ 37.83万$ 37.83万
- 项目类别:
Bioinspired chemical probe approach targeting telomerase reverse transcriptase
针对端粒酶逆转录酶的仿生化学探针方法
- 批准号:1041199510411995
- 财政年份:2020
- 资助金额:$ 37.83万$ 37.83万
- 项目类别:
Lipid signaling in cellular senescence and tissue aging
细胞衰老和组织老化中的脂质信号传导
- 批准号:1066753710667537
- 财政年份:2020
- 资助金额:$ 37.83万$ 37.83万
- 项目类别:
Lipid signaling in cellular senescence and tissue aging
细胞衰老和组织老化中的脂质信号传导
- 批准号:1009561510095615
- 财政年份:2020
- 资助金额:$ 37.83万$ 37.83万
- 项目类别:
相似国自然基金
去泛素化酶USP5调控P53通路在伴E2A-PBX1成人ALL的致病机制研究
- 批准号:81900151
- 批准年份:2019
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
核基质结合区蛋白SATB1调控CCR7抑制急性T淋巴细胞白血病中枢浸润的作用与机制
- 批准号:81870113
- 批准年份:2018
- 资助金额:55.0 万元
- 项目类别:面上项目
成人及儿童急性淋巴细胞白血病的基因组转录组生物信息学分析方法建立及数据分析
- 批准号:81570122
- 批准年份:2015
- 资助金额:60.0 万元
- 项目类别:面上项目
NR3C1基因突变在成人急性淋巴细胞白血病耐药与复发中的作用与机制研究
- 批准号:81470309
- 批准年份:2014
- 资助金额:75.0 万元
- 项目类别:面上项目
儿童和成人急性T淋巴细胞白血病中miRNA和转录因子共调控网络的差异性研究
- 批准号:31270885
- 批准年份:2012
- 资助金额:80.0 万元
- 项目类别:面上项目
相似海外基金
Local translation and viral infection in the airway epithelium
气道上皮的局部翻译和病毒感染
- 批准号:1073628410736284
- 财政年份:2023
- 资助金额:$ 37.83万$ 37.83万
- 项目类别:
Prolidase Inhibitors as Therapeutic Agents for Acute Myeloid Leukemia
脯氨酸酶抑制剂作为急性髓系白血病的治疗剂
- 批准号:1034297010342970
- 财政年份:2022
- 资助金额:$ 37.83万$ 37.83万
- 项目类别:
Prolidase Inhibitors as Therapeutic Agents for Acute Myeloid Leukemia
脯氨酸酶抑制剂作为急性髓系白血病的治疗剂
- 批准号:1057321210573212
- 财政年份:2022
- 资助金额:$ 37.83万$ 37.83万
- 项目类别:
Allosteric Modulators of Src-family Kinases for Acute Myeloid Leukemia
急性髓系白血病 Src 家族激酶的变构调节剂
- 批准号:1047563310475633
- 财政年份:2021
- 资助金额:$ 37.83万$ 37.83万
- 项目类别:
Allosteric Modulators of Src-family Kinases for Acute Myeloid Leukemia
急性髓系白血病 Src 家族激酶的变构调节剂
- 批准号:1031494810314948
- 财政年份:2021
- 资助金额:$ 37.83万$ 37.83万
- 项目类别: